Hydrazone Ribonucleotide Reductase Modulators for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapies targeting ribonucleotide reductase (RR) are nucleoside-based, leading to nonspecific binding and unwanted side effects due to promiscuity, necessitating the development of specific modulators to inhibit RR activity in neoplastic cells for cancer therapy.
Innovation Solution
Development of ribonucleotide reductase modulators (RRmods) with specific structures, such as compounds of formulas (I), (II), and (III), that target and inhibit RR activity by binding to the M-site or C-site of the large subunit of RR, thereby modulating enzyme activity and inhibiting neoplastic cell growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside-based chemotherapies are used to target ribonucleotide reductase, then RR activity can be inhibited, but nonspecific binding occurs leading to unwanted side effects
Solution Approach 1:
The invention segments the binding interaction by designing hybrid molecules that separate the nucleoside-like binding domain (for RR specificity) from the cytotoxic domain. This segmentation allows the molecule to bind specifically to RR through the nucleoside-like portion while avoiding promiscuous binding to other nucleoside-binding proteins, thereby reducing unwanted side effects.
Solution Approach 2:
The patent employs nucleoside-like structures as intermediary elements that mediate specific binding to ribonucleotide reductase without triggering the promiscuous binding associated with conventional nucleoside analogs. These intermediary structures serve as selective recognition elements that bridge the gap between achieving RR inhibition and avoiding off-target effects.
2Reliability
If conventional nucleoside analogs are used, then RR inhibition is achieved, but promiscuous binding to other nucleoside binding proteins occurs
Solution Approach 1:
The invention applies local quality by designing hybrid molecules with distinct functional regions: a nucleoside-like binding domain optimized for specific RR interaction and a cytotoxic domain for therapeutic action. This local differentiation ensures high binding selectivity for RR while maintaining effective inhibition, preventing promiscuous binding to other proteins.
Solution Approach 2:
The patent creates composite hybrid molecules that combine nucleoside-like structural elements with cytotoxic moieties. This composite structure enables the molecule to exhibit selective binding properties of nucleosides for RR while incorporating the therapeutic functionality needed for effective inhibition, thereby achieving both selectivity and efficacy.
Data Source
AI summary
A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a hydrazone or hydrazine ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.